KCNA5 and atrial fibrillation: In a previous investigation, we used an in silico strategy to define optimal KV1.5-targeting drug characteristics, including kinetics and state-dependent binding, that maximize AF-selectivity (i.e., fast pacing-rate selectivity) in human atrial cardiomyocytes (Ellinwood et al., 2017).